Rating #138
Mark Hillman
Hillman Capital Management
Portfolio value
Stocks
Performance
1 Year
+2.22%
Stock Holdings
$
%
1Y
3Y
5Y
10Y
Mark Hillman’s Portfolio: Q1 2026
Top10 stocks: 35.56% of the portfolio
Mark Hillman’s Trades: Q1 2026
Adds
New Buys
Sold Outs
Cuts
1.51ppt
1.13ppt
0.90ppt
0.81ppt
0.34ppt
0.10ppt
0.13ppt
0.44ppt
0.18ppt
0.92ppt
Company Name | Share Count Chg. (%) | Price Paid | Buy Value | Portfolio % Change | |
|---|---|---|---|---|---|
1  FISV | Add +110.36% | $61.88 | $2.62M | 1.51ppt | |
2  ADBE | Add +122.86% | $277.01 | $2.47M | 1.13ppt | |
3  ZBH | Add +21.17% | $91.76 | $892.92K | 0.90ppt | |
4  BF.B | Add +19.17% | $26.86 | $762.42K | 0.81ppt | |
5  BAX | Add +16.91% | $19.35 | $692.32K | 0.34ppt | |
6  CPB | Add +18.12% | $25.68 | $654.69K | 0.10ppt | |
7  NKE | Add +14.33% | $60.64 | $592.21K | 0.13ppt | |
8  KHC | Add +13.76% | $23.52 | $572.31K | 0.44ppt | |
9  EFX | Add +22.36% | $198.61 | $491.96K | 0.18ppt | |
10  PFE | Add +7.21% | $26.62 | $336.29K | 0.92ppt |
Mark Hillman’s Holdings: Q1 2026
Company Name | Primary Industry | Avg. price paid  | Share Count Chg. (%) | No of shares held | Market value | Portfolio % Change | % of Ownership | Holding period | Last Transaction | |
|---|---|---|---|---|---|---|---|---|---|---|
1  BIIB | Biological products | $236.92 | Cut -3.20% | 29.54K | $5.42M | 3.76% 0.38ppt | 0.02% | 26 Quarters | Q1 2026 | |
2  DD | Syn. Resins & Elastomers | $50.13 | Cut -11.52% | 117.90K | $5.40M | 3.75% 0.38ppt | 0.03% | 26 Quarters | Q1 2026 | |
3  WBD | Cable & Pay TV Services | $10.52 | Cut -8.52% | 196.31K | $5.39M | 3.74% -0.15ppt | 0.01% | 16 Quarters | Q1 2026 | |
4  GSK | Pharmaceutical Pres | $30.19 | Cut -14.78% | 97.43K | $5.38M | 3.73% 0.21ppt | 0.01% | 15 Quarters | Q1 2026 | |
5  IFF | Organic Chemicals | $74.06 | Cut -4.29% | 72.77K | $5.28M | 3.67% 0.44ppt | 0.03% | 12 Quarters | Q1 2026 | |
6 PFE | Pharmaceutical Pres | $28.02 | Add +7.21% | 187.94K | $5.28M | 3.66% 0.92ppt | 0.00% | 10 Quarters | Q1 2026 | |
7 ZBH | OrthopedicSupplies | $111.82 | Add +21.17% | 55.70K | $5.04M | 3.50% 0.90ppt | 0.03% | 19 Quarters | Q1 2026 | |
8  CVS | Retail-Drug Stores | $71.21 | Cut -5.89% | 67.46K | $4.85M | 3.36% -0.22ppt | 0.01% | 26 Quarters | Q1 2026 | |
9 BF.B | Beverages | $34.78 | Add +19.17% | 176.44K | $4.66M | 3.24% 0.81ppt | 0.04% | 6 Quarters | Q1 2026 | |
10  KMX | Retail-Auto Dealers & Gas | $68.77 | Cut -1.72% | 109.18K | $4.54M | 3.15% 0.45ppt | 0.07% | 16 Quarters | Q1 2026 | |
11 KHC | Canned & Frozen Foods | $32.54 | Add +13.76% | 201.14K | $4.52M | 3.14% 0.44ppt | 0.02% | 26 Quarters | Q1 2026 | |
12 FISV | - | $78.45 | Add +110.36% | 80.73K | $4.50M | 3.13% 1.51ppt | 0.00% | 3 Quarters | Q1 2026 | |
13  BA | Aircraft Manufacturing | $186.29 | Cut -12.20% | 22.33K | $4.44M | 3.09% -0.39ppt | 0.00% | 24 Quarters | Q1 2026 | |
14 BAX | Surgical Instruments | $31.59 | Add +16.91% | 247.32K | $4.15M | 2.89% 0.34ppt | 0.05% | 11 Quarters | Q1 2026 | |
15 NKE | Rubber & Plastic Footwear | $82.64 | Add +14.33% | 77.91K | $4.12M | 2.86% 0.13ppt | 0.01% | 9 Quarters | Q1 2026 | |
16  MSFT | Prepackaged Software | $186.15 | Add +2.30% | 10.83K | $4.01M | 2.78% -0.44ppt | 0.00% | 26 Quarters | Q1 2026 | |
17 ADBE | Prepackaged Software | $382.33 | Add +122.86% | 16.20K | $3.94M | 2.73% 1.13ppt | 0.00% | 8 Quarters | Q1 2026 | |
18  EL | Perfumes & Cosmetics | $116.23 | Cut -4.80% | 52.17K | $3.74M | 2.60% -1.01ppt | 0.01% | 10 Quarters | Q1 2026 | |
19 CPB | Food Products | $36.18 | Add +18.12% | 166.18K | $3.70M | 2.57% 0.10ppt | 0.06% | 9 Quarters | Q1 2026 | |
20  VZ | Telephone Communications | $51.90 | Cut -0.27% | 65.00K | $3.26M | 2.27% 0.60ppt | 0.00% | 26 Quarters | Q1 2026 |
NEWSLETTER
NEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersOur content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.